Partnerships are a key part of our R&D and business strategy and we are therefore actively seeking new R&D collaborations and in-license opportunities to discover & develop novel innovative medications for hematological oncology indications.
As part of the global scientific community, our scientists search for opportunities to work together and share their scientific findings with other researchers.
Acerta Pharma is motivated to work with those who share our desire to understand tumor biology and drug resistance mechanisms.
Besides resistance to BTK inhibitors, we believe the BPACS platform could be used to profile samples from patients on other therapies, such as venetoclax.
Acerta Quantitative Pharmacology (QCP) consists of scientists with extensive Clinical Pharmacology and Quantitative Pharmacology expertise, who work within aRED center of haematology to support Phase I to Phase IV strategy. In partnership with global QCP scientists at AstraZeneca, we are the subject matter experts in oncology quantitative systems pharmacology, drug-drug interactions, PBPK and pharmacometrics. Finally, we partner with world-class research institutions and cutting-edge Bay Area start-ups to derive novel insights from large clinical studies with application to future clinical development.
Please reach out to us to discuss potential collaborations.